JBIO vs LKFT: fair value comparison
Jade Biosciences, Inc. and Lakefront Biotherapeutics NV · Updated 2026-10-19
JBIO has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. LKFT reports in EUR, so no same-currency fair-value verdict is published for it. Within Healthcare, JBIO currently ranks higher by quality score.
| JBIO | LKFT | |
|---|---|---|
| Verdict | No estimate yet | Awaiting full valuation |
| Last price | $13.47 | $28.86 |
| 12-month range | $8.95–$26.85 | $26.08–$34.64 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #245 of 301 Healthcare | #247 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | — | Contracting |
| Revenue growth | — | Declining |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Downtrend | Mixed |
| 52-week position | The lower-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: JBIO fair value analysis · LKFT fair value analysis